

## SUBJECT INDEX

- A<sub>2</sub> receptors, 203  
 Abstinence syndrome, 671  
 Abuse, 283  
 Acetylcholine, 707, 841  
 Acetylcholinesterase, 867  
 ACh levels, 1075  
 ACTH, 475, 557  
 Active avoidance, 317  
 Active shock avoidance, 533  
 Activity, 77  
 Adenosine, 181, 459, 487  
 Adenylate cyclase, 533  
 Adrenal activity, 913  
 α<sub>2</sub>-Adrenoceptor-stimulated feeding, 391  
 β<sub>2</sub>-Adrenoceptor antagonist, 187  
 α<sub>2</sub>-Adrenoceptors, 749  
 β-Adrenoceptors, 533  
 Adult offspring behavior, 323  
 Age effects, 361  
 Aggression, 867, 919  
 Aggressive mice, 111  
 Agonist activity, 939  
 Alcohol, 293, 667  
 Alcohol consumption, 1061  
 Alcohol-preferring and -nonpreferring rats, 1061  
 Allesthesia, 117  
 Alpha-1-acid glycoprotein, 1043  
 Alpha-1 adrenoceptors, 927  
 Alpha-2 adrenoceptor agonists, 927  
 Alpha-2 adrenoceptor antagonists, 927  
 Alpha-2 adrenoceptors, 927  
 Alpha-adrenoreceptor, 831  
 Alpha- and beta-receptors, 133  
 Alpha-flupentixol and spatial navigation, 211  
 Alternation task, 49  
 Alternation test, 283  
 Alzheimer's disease, 841  
 Amfonelic acid, 977, 983  
 2-Amino-7-phosphonoheptanoic acid, 733  
 Amiodarone, 87  
 Amnesia, 187, 787, 873  
 Amphetamine, 71, 147, 355, 361, 577, 581, 683, 723, 769, 1017  
 d-Amphetamine, 55, 65, 241, 249, 447, 711, 857  
 Analgesia, 505, 613, 661, 717, 727, 897, 939, 961  
 Animal newborn, 1067  
 Anisomycin, 867, 873, 1003  
 Anorexia, 147, 275, 819  
 Antagonist, 933  
 Antagonist activity, 939  
 Anticonvulsant activity, 27  
 Anticonvulsants, 595, 733, 823  
 Antidepressant properties, 111  
 Antinociception, 657  
 Anxiety, 151, 181, 801, 807, 919  
 Anxiety model, 777  
 Anxiogenic-like effect, 259  
 Anxiolytic method, 773  
 Anxiolytic-like effect, 259  
 Anxiolytics, 331, 807  
 Apomorphine, 43, 71, 77, 141, 151, 249, 533, 589, 651, 723, 815  
 Appetite, 769  
 Arcuate nucleus, 391  
 Area postrema, 1033  
 Arousal, 919  
 Aspartame, 17  
 Atenolol, 807  
 Atropine, 309, 495, 867, 1075  
 Atropine methyl nitrate, 971  
 Atropine sulfate, 175, 971  
 Attention, 399  
 Aversion, 431  
 Aversive and nonaversive tasks, 885  
 Aversive environmental stimuli, 857  
 Avoidance, 677  
 Azapropfen, 495  
  
 BAER, 757  
 Barbiturates, 897  
 Barrel rotation, 629  
 Behavior, 27, 885  
 Behavioral tolerance, 267, 283  
 Behavioral toxicity, 819  
 Behavioral toxicology, 17  
 Benzodiazepine, 181, 613, 743, 801, 823, 901  
 Benzodiazepine inverse agonist, 163  
 Benzodiazepine receptor, 667  
 Benzodiazepine receptor antagonists, 671, 901  
 Benzodiazepine-methylxanthine interaction, 773  
 Beta-alanine, 505  
 Beta-carbolines, 27  
 B-HT 920, 815  
 Bicuculline, 357, 563  
 Blood ethanol levels, 431  
 BMY-14,802, 87  
 Body weight, 1025  
 Brain regions, 791  
 Brain-stimulation reward, 977, 983  
 Brown adipose tissue, 301  
 Buffer, 831  
*Bufo regularis*, 83  
 Buspirone, 87, 227, 259, 1049  
  
 C57BL, 241  
 Caffeine, 181, 399, 459, 773, 1017  
 Calcium antagonist, 595  
 Cat, 207, 459, 519, 671, 861  
 Catalepsy, 621, 661, 717  
 Catch-up growth, 957  
 Catecholamines, 9, 629  
 CD-1, 241  
 Central and peripheral benzodiazepine receptors modulation, 879  
 Cerebellum, 827  
 Cerebral cortex, 827, 831  
 Cerebral laterality, 293  
 Cerebral lateralization, 425  
 Cerebrospinal fluid (CSF), 227  
 CF-1, 241  
 CGS 8216, 671  
 CH-38083, 927  
 Chemoconvulsions, 233  
 Chick, 187  
 Chicken, 377  
 Chloramphenicol, 867  
 Chlordiazepoxide, 123, 743, 801  
 Chloro-2(1-piperaziny)pyrazine (MK-212), 657  
 p-Chlorophenylalanine, 815  
 Chlorophenylpiperazine (mCPP), 657  
 Cholinergic, 495  
 Cholinergic hypofunction, 841  
 Cholinergic system, 787  
 Chronic administration, 227  
 Chronic naltrexone, 727  
 Chronic neuroleptics, 1057  
 Chronic stress, 737  
 Chronic treatment, 1075  
 Cigarette smoking, 677  
 Circadian, 1043  
 Circadian clock, 901  
 Circadian rhythm, 475, 491  
 Circling, 849  
 Cisplatin, 207  
 Clonazepam, 367, 773  
 Clonidine, 133, 151, 383, 749  
 Cocaine, 71, 267, 447, 463, 527, 691, 857, 1017  
 Cognitive performance, 399  
 Colchicine, 301  
 Cold, 1025  
 Concurrent schedules, 347  
 Conditional discriminations, 439  
 Conditioned fear, 469  
 Conditioned place aversion, 355  
 Conditioned place preference, 355  
 Conditioned saccharin aversion, 819  
 Conditioned stereotypy, 249  
 Conditioned suppression, 807  
 Conditioned Suppression of Drinking (CSD), 801  
 Conditioned taste aversions, 1, 17, 1033  
 Conditioning, 581  
 Conflict, 1025  
 Conflict behavior, 801, 807  
 Continuous reinforcement, 55, 65  
 Convulsions, 367  
 Copulatory pelvic thrusting, 169  
 Core temperature, 331  
 Corpus striatum, 425  
 Cortico-striatal pathway, 337  
 Corticosterone, 37, 557  
 Corticotropin releasing factor, 197  
 Corticotropin-releasing hormone, 919  
 Cortisol, 9  
 Cough reflex, 357  
 m-CPP, 37  
 CRF, 967  
 CRF antagonist, 197  
 Cross-sensitization, 581  
 Cumulative food intake, 147  
 Cycloheximide, 787  
 Cyclohexyladenosine (CHA), 487  
 Cyclopentyladenosine (CPA), 487  
 Cyproheptadine, 415, 585  
 Cysteamine, 629  
  
 D1, 691, 1033

- D1 and D2 dopamine receptors, 141  
 D-1/D-2 receptors, 203  
 D2, 691, 1033  
 DAGO, 469  
 DBA, 241  
 p,p'-DDT, 993  
 Decortication and neuroleptics, 211  
 Deer mouse, 613  
 Delayed matching-to-sample, 439  
 Delta-receptor, 469  
 Denervation supersensitivity, 337  
 Depressants, 283  
 Depression, 737, 913, 927  
 Deprivation, 383  
 Desipramine, 533, 967  
 Dexfenfluramine, 1025  
 Dextrofenfluramine, 573  
 DFP, 867  
 5,7 DHT, 993  
 Diazepam, 27, 367, 479, 613, 671, 807  
 Differential-reinforcement-of-low-rate, 643  
 Dihydroergosine, 111  
 Discrimination, 971  
 Discrimination accuracy, 707  
 Discriminative stimulus, 711  
 Dopamine, 43, 95, 221, 249, 337, 553, 621, 945, 949, 977, 993, 1033, 1049, 1067  
 Dopamine D<sub>2</sub> receptors, 447, 815  
 Dopamine receptors, 691, 717  
 Dopamine release, 71  
 Dopamine turnover, 425  
 Dopaminergic sites, 151  
 Dorsal raphe, 625  
 Dose, 1009  
 Dose-response, 361  
 Double blind, 1065  
 DPDPE, 469  
 Drinking, 415  
 Drive, 1025  
 DRL schedule of reinforcement, 967  
 Drug concentration, 347  
 Drug discrimination, 87, 361, 607, 1017  
 Drug discrimination learning, 1  
 Drug interactions, 309, 479, 711, 807, 1017  
 Drug reinforcement, 347  
 Drug self-administration, 347  
 Drug-adulterated food, 891  
 Dyskinesia, 505
- Eating time, 133  
 EEG, 987  
 EEG activity, 861  
 EEG spectral analysis, 27  
 EKG, 83  
 Electrodermal activity, 9  
 Electromyography, 9  
 Emesis, 207  
 Endogenous modulator, 1043  
 Endogenous opiate system, 737  
 Endogenous opioids, 469  
 Environment-specificity, 581  
 Environmentally-induced analgesia, 961  
 Epileptic seizures, 405  
 Ethanol, 233, 361, 533, 1071  
 Ethanol self-administration, 431  
 Ethanol sensitivity, 827  
 Ethanol withdrawal, 163  
 Ethanolamine-O-sulfate, 275  
 Ethylcholine mustard aziridinium, 841  
 Etilopride, 717  
 Evolutionary origin of central reward mechanism, 355
- Excitatory amino acids, 337, 733  
 Exploration, 853  
 Exploratory behavior, 487  
 Extinction, 65
- Fasting, 101  
 Fear and/or anxiety, 569  
 Feed refusal, 819  
 Feeding, 133, 275, 415, 769, 907  
 Feeding rate, 133  
 d-Fenfluramine, 411  
 FEP, 757  
 Fetal Alcohol Syndrome, 283  
 FG-7142, 233, 671  
 Fixed interval, 267  
 Fixed-consecutive-number, 439  
 Fixed-interval performance, 643  
 Fixed-interval schedule, 479  
 Fixed-ratio, 643  
 Fixed-ratio schedule, 347  
 Flash evoked potentials, 511  
 Fluphenazine, 71, 1057  
 Flurazepam, 87  
 Food deprivation, 347  
 Food intake, 367, 483, 573  
 Food motivation, 1025  
 Food restriction, 957  
 Food satiation, 347  
 Force-proportional reinforcement, 499  
 Formalin test, 469  
 FSH, 157
- GABA, 111, 275, 357, 505, 563, 625, 667, 849, 1067  
 GABA agonists, 879  
 GABA and glycine antagonists, 169  
 GABA-transaminase, 275  
 Genital grooming, 853  
 Gepirone, 259, 1049  
 Glucose, 553  
 Glutamate, 621  
 Glutamate receptors, 337  
 Glutamic acid, 733  
 Glutamic acid diethyl ester, 733  
 Glycine, 505, 993  
 Goldfish, 355  
 Gonadotropins, 157  
 Grooming, 853  
 Growth hormone, 37  
 Guinea pigs, 421, 1057
- H<sub>1</sub>-antagonists, 861  
 [<sup>3</sup>H]Dopamine synaptosomal uptake, 699  
 Habenula nucleus, 77  
 Haloperidol, 87, 95, 589, 621, 683, 967, 1033  
 Hamsters, 589  
 Head twitch behavior, 585  
 Heart rate, 9, 83  
 Heroin, 527, 1009  
 Hippocampectomy and neuroleptics, 211  
 Hippocampus, 95  
 Homotaurine, 607  
 Hooded rats, 511  
 [<sup>3</sup>H]PCP binding, 699  
 HPLC, 1071  
 5-HT, 111  
 5-HT<sub>3</sub> antagonists, 207  
 5-HT<sub>1A</sub> receptor, 259, 491, 1049  
 5-HT<sub>1B</sub> receptor, 491  
 Humans, 117, 483, 677  
 Hunger, 117
- 6-Hydroxydopamine, 43, 577  
 5-Hydroxytryptamine, 317, 797, 907  
 Hyperactivity, 577, 823  
 Hyperalgesia, 961  
 Hyperlocation, 835  
 Hyperlocomotion, 835  
 Hyperprolinemia, 885  
 Hyperreactivity, 637  
 Hypothalamic nuclei, 101  
 Hypothalamo-pituitary-adrenal axis, 323  
 Hypothalamus, 101, 411, 629  
 Hypothermia, 141, 511, 533, 661
- ICI 118,551, 187  
 Idazoxan, 749  
 Iminodipropionitrile, 1003  
 Imipramine, 37, 737  
 Immobilization, 1071  
 Immune function, 913  
 Incentive, 1025  
 Ingestive behavior, 117  
 Inhalation, 987  
 Inhibition, 637  
 Inhibitory avoidance, 563  
 Inositol 1,4,5-trisphosphate, 827  
 Insomnia, 1065  
 Insulin, 553  
 Intertrial interval, 55  
 Intoxication, 667  
 Intracortical AF64A, 841  
 Intrathecal, 505  
 Intrathecal treatments, 169  
 Intravenous self-administration, 1009  
 Ion, 841  
 Ipsapirone, 259, 1049  
 Island-mainland populations, 613  
 Isobologram, 1017  
 Isolation, 637  
 Isolation distress, 197
- Kappa-receptor, 469  
 Ketamine, 405, 511  
 Keypeck, 267  
 Kindling, 463
- L-5-HTP, 259  
 LH, 157  
 Large neutral amino acids, 17  
 Latency to feed, 147  
 Latent inhibition, 123  
 Lateral hypothalamus, 275  
 Learning, 495  
 Learning/memory, 841  
 Lesion, 275  
 Lesions, dorsomedial hypothalamic nucleus, 957  
 Lever-pressing, 309  
 Lidocaine, 463  
 Lindane, 367  
 Lithium, 453  
 Locomotion, 853  
 Locomotor activity, 129, 221, 487, 581, 625, 683, 901, 1003  
 Long sleep and short sleep mice, 827  
 Long-term, 37  
 Long-term memory, 873  
 Loratadine, 861  
 Lordosis, 421  
 LSD, 191  
 Luteinizing hormone releasing hormone (LHRH), 853  
 LY 171555, 95, 1033

- Male and female rats, 707  
Male rats, 1071  
Marijuana, 483  
Mating behavior, 377  
Mazindol, 71  
Mecamylamine, 933  
16-Me cyprenorphine (Rx 8008M), 469  
Median raphe, 625  
Melatonin, 157  
Memory, 495, 749, 971  
Memory consolidation, 563  
Mental stress, 9  
Meperidine, 87  
Mescaline, 191  
Met-enkephalin, 791  
Metergoline, 601  
Methadone, 643  
3-Methoxytyramine, 553  
Methylatropine, 175  
3,4-Methylenedioxymethamphetamine (MDMA), 835  
Methysergide, 657, 787  
Metrazol, 405  
MHPG-SO<sub>4</sub>, 569, 791  
Mice, 487, 563, 727, 787  
Microsomal flavin-containing monooxygenase, 87  
Midazolam, 901  
MIF-1, 737  
Milacemide, 993  
Mitochondria, 873  
MK-801, 595, 621  
Molindone, 439  
Monkeys, 607  
Monoamine, 1049  
Monoamine metabolite, 1049  
Monosodium L-glutamate, 391  
Montgomery's conflict test, 259  
Morphine, 129, 241, 519, 581, 589, 683, 717, 939, 961, 983  
Motion sickness, 207  
Motor activity, 241, 797  
Motor behavior, 919  
Motor impairment, 733  
Mouse, 667, 777  
Mouse motility, 1075  
Mouse strains, 241  
Mouse-killer rats, 111  
MR/Har and MNRA/Har Maudsley rat strains, 801  
Mu-receptor, 469  
Multiple schedule, 267  
Muscarinic receptors, 543  
Muscimol, 563, 625, 897  
Mycotoxins, 819  
Myocardial sensitivity, 475  
Myoclonus, 993  
*Myristica fragrans*, 83
- N-0437, 447  
N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine (BTCP), 699  
NaCl intake, 773  
N-allylnormetazocine, 711  
Naloxone, 511, 563, 589, 613, 737, 961, 977  
Naltrexone, 563, 651, 683  
Natural killer cells, 913  
N-dealkylation, 87  
Neonatal brain endocrine ontogenesis, 323  
Neonate, 453  
N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, 141  
N-ethylcarboxamidoadenosine (NECA), 487  
Neural change, 249  
Neurochemical asymmetry, 425  
Neurochemistry, 227  
Neuroendocrinology, 913  
Neuroleptics, 337, 439, 499  
Neuroleptics and extinction, 211  
Neuroleptics and spatial navigation, 211  
Neuronal uptake, 475  
Neuropeptide Y, 391  
Neuropharmacology of feeding, 391  
Nicotine, 221, 479, 677, 857, 933  
Nicotine blood level, 677  
Nicotine gum, 677  
Nimodipine, 595  
Nisoxetine, 983  
NMDA, 621  
NMDA receptor antagonist, 595  
NMDA receptors, 405  
N-n-propylmorphine, 141  
Nociception, 601  
Nonaggressive, 867  
Nonbenzodiazepine anxiolytics, 1049  
Noradrenaline, 133  
Noradrenaline metabolism, 569  
Noradrenaline release, 791  
Noradrenergic, 181  
Noradrenergic sites, 151  
Noradrenergic system, 421  
Norepinephrine, 101, 475, 1049  
Novelty, 683  
Nucleus accumbens, 577, 769  
Nucleus basalis, 841  
Nutmeg, 83
- Ochratoxin A, 819  
Off-baseline conditioned suppression, 123  
11-OH- $\Delta^8$ -THC-DMH, 661  
8-OH-DPAT, 227, 259, 573, 797  
Olfactory tubercle, 577  
One-trial passive avoidance learning, 187  
Ontogenesis, 405  
Open field, 533, 629, 737, 797  
Operant behavior, 49, 949  
Operant conditioning, 495  
Opiates, 939, 961  
Opioid, 961  
Opioid antagonists, 563  
Opioid system, 117  
Opioid-dopamine interactions, 717  
Opioids and feeding, 391  
Oral route, 347  
Organophosphonates, 49  
Overdose, 365  
Overfeeding, 101  
Oxymorphone, 939  
Oxymorphone-6-spirohydantoin, 939
- Pain, 505, 601, 657  
Pain thresholds, 939  
Palatability, 1025  
Pantethine, 629  
Para-ventricular hypothalamus, 133  
Paraventricular nucleus, 907  
Partial reinforcement, 55, 65  
Pavlovian conditioning, 365, 469  
Pentobarbital, 347, 355, 357, 365, 711, 891  
Pentothal, 897  
Periaqueductal gray substance, 853  
*Peromyscus maniculatus*, 613  
Pharmacological conditioning, 249
- Phase shift, 901  
Phase-response curve, 901  
Phencyclidine, 1, 87, 711  
Phencyclidine (PCP) and derivatives, 699  
Phenobarbital, 807, 891  
2-(Phenylamine) adenosine (CV-1808), 487  
Phenylpropanolamine, 147  
Phenytol, 367  
Physical dependence, 1009  
Physical exercise, 573  
Physostigmine, 309, 511  
Picrotoxin, 357, 563  
Pigeons, 227, 267, 415, 439, 607, 643, 711  
Pimozide, 249, 499, 527, 691, 949  
Piribedil, 815  
Pituitary cyclic AMP, 557  
Place conditioning, 129, 431  
Place preference behavior, 683  
Plasma amino acids, 1071  
Plasma renin activity, 1061  
Platelets, 1043  
PmP, 259  
Power spectrum analysis, 987  
Prazosin, 421, 831  
Preference, 933  
Prenatal stress, 425  
Primate, 495  
Prolactin, 9, 37, 157, 557  
Proline, 885  
Propranolol, 133, 807  
Protein synthesis inhibition, 873, 1003  
Psychological stress, 569  
Psychosis, 337  
Punished drinking test, 323  
Punishment, 743  
Puromycin, 749  
Pyriform cortex, 463
- Quinpirole, 1033  
Quipazine, 585
- Radial maze, 87  
Radioligand binding, 827, 831  
Rats, 1, 17, 49, 55, 65, 123, 133, 151, 169, 191, 233, 259, 275, 283, 317, 405, 411, 453, 463, 469, 499, 527, 557, 601, 621, 743, 757, 797, 819, 873, 907, 945, 949, 971, 1009, 1067  
Rat brain regions, 569  
Rate-dependency, 241, 801  
Receptor, 87  
Receptor binding, 743  
Receptor reserve, 141  
Recovery, 841  
Regional brain serotonin levels, 993  
Reinforcement, 43, 129, 431, 933, 1009  
Reinforcement schedule history, 643  
REM sleep, 861  
Renin-angiotensin system, 1061  
Repeated acquisition, 439  
Repeated treatment, 95  
Reserpine, 815  
Resistance to extinction, 55  
Respiration, 357  
Respiration rate, 9  
Respiratory sinus arrhythmia, 175  
Response force, 499  
Response time, 399  
Retina, 191  
Reward, 411  
Rhesus monkeys, 347, 691  
Ritanserin, 787

- Ro 15-1788, 233, 613, 617, 901  
 Ro 15-4513, 163, 233, 671  
 Ro 5-4864, 367  
 Rotarod, 699  
 Route of administration, 677
- Salt, 945  
 Satiety, 133  
 Satisfaction, 933  
 Scent, 613  
 SCH 23390, 71, 141, 585, 651, 691, 717, 945  
 Schedule-controlled behavior, 479  
 Schedule-induced polydipsia, 949  
 Schizophrenia, 337  
 Scopolamine, 241, 309, 723  
 Scopolamine hydrobromide, 707  
 Scopolamine methylbromide, 707  
 Sedation, 861  
 Seizures, 733, 1067  
 Self-administration, 43, 483, 527, 607, 691  
 Self-stimulation, 411  
 Semen, 377  
 Sensitization, 71, 77  
 Sensorimotor integration, 949  
 Sensory-evoked potentials, 757  
 SEP, 757  
 Serotonergic neuron, 815  
 Serotonergic system, 787  
 Serotonin, 259, 415, 491, 573, 585, 601, 1003, 1043, 1049  
 Serotonin (5-HT), 657  
 Serotonin antagonists, 657  
 Serotonin syndrome, 835  
 Sesquiterpenes, 1065  
 Set-point, 1025  
 Sexual behavior, 421  
 Sham-feeding, 447  
 Shock predictability, 569  
 Shock-induced aggression, 867  
 Sigma, 87  
 SK&F 38393, 815, 849, 945, 1033  
 SKF-10,047, 87  
 Skin blood flow, 601  
 Skin temperature, 601  
 Sleep, 27  
 Sleep-wakefulness, 519  
 Slow wave sleep (S1), 459  
 Slow wave sleep (S2), 459  
 SM-3997, 1049  
 Smoking, 933
- Social behavior, 483, 637  
 Solvent abuse, 757  
 Soman, 49  
 Spasmodic dyskinesias, 1003  
 Spatial learning, 543  
 Spinal cord, 831, 897  
 Spontaneous activity, 661  
 Spontaneous alternation, 723  
 Spontaneous firing rate, 95  
 Spontaneous locomotor activity, 857  
 Squirrel monkeys, 309, 657, 919  
 Static ataxia, 661  
 Stereoselectivity, 661  
 Stereotyped behavior, 203, 589  
 Stereotypy, 77, 147, 249  
 Stimulus control, 283  
 Strains, 727  
 Stress, 557, 585, 791, 879, 913, 919, 1071  
 Stress-induced analgesia, 469  
 Striatum, 71, 221, 1003, 1067  
 Stroop test (numerical), 399  
 Strychnine and bicuculline, 169  
 Substantia nigra, 849, 1067  
 Suckling, 453  
 Sucrose, 383, 447, 499  
 Sudden death, 331  
 8-(p-Sulphophenyl)theophylline (8-pSPT), 487  
 Sulpiride, 71, 141, 651  
 Superior colliculus, 511  
 Supersensitivity, 95, 585, 727  
 Sweet preference, 117  
 Sympatho-adrenal activation, 9
- Tail flick test, 601  
 Tail posture, 425  
 Tamoxifen, 87, 377  
 Tardive dyskinesia, 1057  
 Taste aversion, 819  
 TCP, 87  
 Temperature regulation, 367  
 Testosterone, 377  
 TFMPP, 361  
 THC, 483  
 $\Delta^9$ -THC, 661  
 Theophylline, 487  
 Thermogenesis, 301  
 Thermoregulation, 301  
 Thienyl-phencyclidine (TCP) and derivatives, 699  
 Thirst, 945  
 Time course, 309, 971
- Time of injection, 791  
 Time-response effects, 949  
 Tobacco, 933  
 Tolerance, 267, 365, 519  
 Tolerance development, 543  
 Toluene, 283, 757, 987  
 Toxicity, 733  
 Treadmill, 797  
 Tremor, 823  
 Triazolam, 901  
 Trifluoromethylphenylpiperazine (TFMPP), 657  
 Trihexyphenidyl, 87  
 Tryptamine, 317, 907  
 Tubocurarine, 87  
 Turning behavior, 425  
 Type 2 receptors, 823
- U50,488H, 469  
 Ultrasonic calls, 197  
 Underfeeding, 101  
 Upregulation, 727  
 Uptake, 1049
- Vagal tone monitoring, 175  
 Valepotriates, 1065  
 Valerian, 1065  
 Vascular activity, 9  
 Ventral tegmental area, 625  
 Ventricular action potential, 83  
 Ventromedial hypothalamus, 301  
 Visual and auditory discrimination, 707  
 Visual-evoked potential, 191  
 VMH lesions, 301
- Water intake, 383, 651  
 Wet dog shaking, 533  
 Wheel running, 17  
 White and black test box, 777  
 Withdrawal, 519  
 Word recall, 399  
 Writhing, 505
- Xylazine, 207
- Yawning, 815  
 Yohimbine, 151
- Zimeldine, 415  
 ZK 93426, 671

## AUTHOR INDEX

- Abd Allah, G., 83  
 Agrasal, C., 157  
 Ahlenius, S., 797  
 Akiyoshi, J., 491  
 Alexander, G. J., 939  
 Alkondon, M., 867  
 Allen, J. D., 949  
 Alling, C., 629  
 Allweis, C., 873  
 Altman, H. J., 801  
 Angelucci, L., 323  
 Anton, R. F., 163  
 Apfelbaum, M., 117  
 Aranko, K., 823  
 Arendash, G. W., 841
- Arnon, E., 377  
 Asin, K. E., 1033  
 Aulakh, C. S., 37
- Baldwin, H. A., 181  
 Balfour, D. J. K., 857  
 Barber, D. J., 447  
 Bardo, M. T., 683  
 Barraclough, S., 399  
 Barrett, J. E., 227, 309  
 Bassett, J. R., 475  
 Becker, H. C., 163  
 Bellinger, L. L., 957  
 Ben-Or, S., 873  
 Bennett, R. H., 677
- Benowitz, N. L., 677  
 Bercovitz, H., 55  
 Berens, K., 439  
 Berge, O.-G., 601  
 Bernardis, L. L., 957  
 Beyer, C., 169, 897  
 Biggio, G., 671  
 Bijak, M., 95, 585  
 Blake, M. J., 743  
 Blanková-Vaňková, S., 405  
 Boja, J. W., 361  
 Bolger, G. T., 595  
 Boomsma, F., 9  
 Bradbury, G. E., 77
- Brady, J. V., 483  
 Branch, M. N., 267  
 Britton, K. T., 967  
 Bubser, M., 621
- Caballero, A., 519  
 Cabanac, M., 1025  
 Cadet, J. L., 1003  
 Calcagnetti, D. J., 469  
 Cao, L., 553  
 Caporali, M. G., 203  
 Capriotti, R. M., 483  
 Carey, R. J., 577  
 Carney, J. M., 1017  
 Castellano, C., 563

- Catalani, A., 323  
 Chance, W. T., 553  
 Chaouloff, F., 573  
 Chatterje, N., 939  
 Chaudieu, I., 699  
 Cherek, D. R., 677  
 Chicheportiche, M., 699  
 Chicheportiche, R., 699  
 Church, A. C., 749  
 Clark, D. E., 819  
 Cleary, J. P., 439  
 Cockroft, R., 147  
 Coen, K. M., 1009  
 Coenen, A. M. L., 27  
 Colle, L. M., 769  
 Commissaris, R. L., 801, 807  
 Compton, D. R., 661  
 Cooper, S. J., 447, 945  
 Copeland, R. L., Jr., 987  
 Corda, M. G., 671  
 Corrigan, W. A., 1009  
 Coscina, D. V., 275  
 Costa, S. M., 885  
 Costall, B., 777  
 Cramer, C. P., 453  
 Creighton, D., 331  
 Cunningham, M. G., 463
- Dacanay, R. J., 1  
 Dai, S., 1009  
 Danguir, J., 573  
 Davies, D. C., 187  
 Dawson, R., Jr., 391  
 de Andres, I., 519  
 Dellinger, J. A., 175  
 Dgany, O., 377  
 Dingemans, J., 823  
 Donoso, A. O., 853  
 Durcan, M. J., 487, 667  
 Dworkin, S. I., 743  
 Dykstra, L. A., 439
- Eells, J. T., 191  
 Ehrensing, R. H., 737  
 Eide, P. K., 601  
 Elghozi, J.-L., 573  
 Ellison, G., 1057  
 Elsmore, T. F., 495, 971  
 Emmett-Oglesby, M. W., 129  
 Emurian, C. S., 483  
 Engel, J. A., 259  
 Esquifino, A. I., 157  
 Evans, J. A. C., 77  
 Evenden, J. L., 211
- Fahn, S., 993, 1003  
 Falk, J. L., 773  
 Fanselow, M. S., 469  
 Fantino, M., 117, 1025  
 Feder, H. H., 421  
 Feldman, M. J., 957  
 Feldon, J., 55, 65, 123  
 Ferber, C., 1025  
 Fermanian, J., 637  
 Fernandez, A., 671  
 File, S. E., 151, 181, 823  
 Fischer, J. E., 553  
 Fischman, M. W., 483  
 Flaherty, C. F., 383
- Fletcher, P. J., 317, 907  
 Flexner, J. B., 749  
 Flexner, L. B., 749  
 Foltin, R. W., 483  
 Fontana, D. J., 807  
 Foreman, N., 399  
 Fotuhi, M., 769  
 Fowler, S. C., 499  
 Frances, H., 637  
 Freed, W. J., 337, 733  
 Fride, E., 425, 873  
 Fundarò, A., 1075  
 Fung, Y. K., 221  
 Furukawa, T., 815
- Gabriel, S. M., 391  
 Galloway, M. P., 993  
 Gambini, B., 323  
 Gargiulo, P. A., 853  
 Gauvin, D. V., 1017  
 Gear, J. C., 987  
 Genovese, R. F., 495  
 Gerber, G. J., 527  
 Ghosh, T. K., 987  
 Gilbert, D. B., 945  
 Giorgi, O., 671  
 Giovino, A. A., 581  
 Giuliani, A., 323  
 Goeders, N. E., 743  
 Goy, R. W., 421  
 Gramlich, C. A., 463  
 Grant, K. A., 607  
 Grant, V. L., 355  
 Griffith, J. A., 367  
 Grigson, P. S., 383  
 Grothues, A., 415  
 Grupp, L. A., 431, 1061  
 Güntürkün, O., 415
- Haas, N., 301  
 Haass, M., 37  
 Harbaugh, C. R., 197  
 Harland, R. D., 1017  
 Harrington, G. M., 801  
 Harro, J., 879  
 Harsing, L. G., Jr., 927  
 Hauger, R. L., 913  
 Hautkappe, A., 415  
 Heilig, M., 629  
 Helmstetter, F. J., 469  
 Hendrie, C. A., 961  
 Henningfield, J. E., 933  
 Hernandez, L., 411  
 Herr, D. W., 831  
 Herz, A., 129  
 Hetzler, B. E., 511  
 Hill, J. L., 37  
 Hillegaart, V., 797  
 Hiroi, N., 249  
 Hirose, A., 1049  
 Hizami, R., 141  
 Hjorth, S., 259  
 Hoebel, B. G., 411  
 Holder, M. D., 17  
 Hole, K., 601  
 Holloway, F. A., 1017
- Ida, Y., 569, 791  
 Igoin, L., 117  
 Innes, D. G. L., 613  
 Insel, T. R., 197, 919
- Introini-Collison, I. B., 563  
 Inturrisi, C. E., 727  
 Irwin, M. R., 913  
 Itoh, K., 787  
 Izenwasser, S., 743, 983
- Jaax, N. K., 49  
 Jackson-Lewis, V., 1003  
 Jamrozik, Z., 993  
 Jansen, H. T., 175  
 Johnston, A. L., 151, 823  
 Johnston, J. L., 101  
 Jolly, S. K., 807  
 Jones, B. J., 777
- Kalant, H., 1009, 1061  
 Kamei, J., 357  
 Kamenka, J.-M., 699  
 Kameyama, T., 651, 787  
 Kant, G. J., 557  
 Kapocsi, J., 927  
 Kastin, A. J., 737  
 Kasuya, Y., 357  
 Katz, M., 1003  
 Cavaliers, M., 613  
 Kawashima, K., 787  
 Kelly, M. E., 777  
 Kelly, T. H., 677  
 Khazam, C., 331  
 Kiivet, R.-A., 879  
 Kiritsy-Roy, J. A., 717  
 Kirkpatrick, M. A., 499  
 Kliner, D. J., 347  
 Klitenick, M. A., 625  
 Knapp, C. M., 977  
 Kodis, M., 957  
 Komisaruk, B. R., 169, 897  
 Koob, G. F., 967  
 Kometsky, C., 977, 983  
 Kosse, K., 891  
 Kreuscher, S. P., 727  
 Kreuter, L., 141  
 Kulkarni, S. K., 233  
 Kumasaka, Y., 1049  
 Kuranaga, H., 491  
 Kuribara, H., 773
- Larson, A. A., 505  
 Laties, V. G., 283  
 Lau, Y.-S., 221  
 Lecrubier, Y., 637  
 Leenen, F. H. H., 1061  
 Lett, B. T., 355  
 Leu, J. R., 971  
 Levin, E. D., 933  
 Lienard, C., 637  
 Lindahl, O., 1065  
 Lindwall, L., 1065  
 Lister, R. G., 667  
 Little, P. J., 661  
 Lorentz, G., 323  
 Lucot, J. B., 207  
 Lund, A., 601  
 Lynch, M. R., 577
- McCann, D. J., 87  
 McCarthy, M. M., 897  
 McClelland, R. C., 411
- McCloskey, T. C., 801, 807  
 McEwen, B. S., 421  
 McFarland, D. J., 723  
 McGaugh, J. L., 563  
 McKearney, J. W., 657  
 McLaughlin, C. R., 453  
 McLean, J. H., 737  
 McMillan, D. E., 711
- Madon, M., 399  
 Mailman, R. B., 831  
 Manev, H., 111  
 Mareš, P., 405  
 Markowitz, R. A., 309  
 Marriage, B. J., 101  
 Martin, B. R., 661  
 Martinez, R. A., 589  
 Marzanatti, M., 861  
 Mastropaolo, J. P., 1  
 Matsumoto, S., 815  
 Matsuo, N., 815  
 Matteucci, M. J., 757  
 Mattson, S., 293  
 Mechoulam, R., 661  
 Mehrabani, P., 475  
 Mehta, A., 399  
 Meisch, R. A., 347  
 Mekkawy, H., 83  
 Melchior, J.-C., 117  
 Melk, A.-M., 511  
 Meller, E., 141  
 Meyer, E. M., 841  
 Meyerhoff, J. L., 557  
 Meyerson, L. R., 1043  
 Michaelis, R. C., 1017  
 Mikolášová, S., 405  
 Milakofsky, L., 1071  
 Miller, J. M., 1071  
 Mittleman, G., 211  
 Modrow, H. E., 49  
 Moleman, P., 9  
 Molinengo, L., 1075  
 Monopoli, A., 861  
 Montana, W. E., 1033  
 Moore, C., 399  
 Moralí, G., 169  
 Moreira, J. C. F., 885  
 Morgan, P. F., 487  
 Moshé, S. L., 1067  
 Moskowitz, K. H., 1  
 Mougey, E. H., 557  
 Mouton, P. R., 841  
 Murphy, D. L., 37  
 Muscat, R., 133  
 Mück-Seler, D., 111
- Nabeshima, T., 787  
 Nabil, Z., 83  
 Nader, M. A., 227, 643  
 Nagashima, M., 815  
 Nagayama, H., 491  
 Nakamura, M., 1049  
 Nakayama, S., 651  
 Natelson, B. H., 331  
 Naylor, R. J., 777  
 Neisewander, J. L., 683  
 Newman, J. D., 919  
 Nobrega, J. N., 275
- O'Neill, S. K., 595

- Ocheret, D., 1043  
Ogawa, M., 357  
Oguchi, M., 791  
Oliveto, A. H., 439  
Olson, G. A., 737  
Olson, R. D., 737  
Ongini, E., 861  
Orsetti, M., 1075  
Otienweller, J. E., 331
- Parkinson, J. K., 971  
Paterson, I. A., 907  
Pavone, F., 563  
Payne, J. M., 187  
Peris, J., 71  
Peričić, D., 111  
Petitjean, F., 459  
Pezzoli, G., 993  
Picker, M. J., 439  
Pierce, R. C., 683  
Pignatiello, M. F., 737  
Pöld, M., 879  
Popoli, P., 203  
Pradhan, S. N., 987  
Preston, E., 301  
Pryor, G. T., 757
- Rabin, R. A., 87  
Rägo, L., 879  
Ray, A., 867  
Rebert, C. S., 757  
Rees, D. C., 283  
Rens-Domiano, S., 87  
Reynolds, E. E., 749  
Rigaud, D., 117  
Riley, A. L., 1  
Riley, E. P., 293  
Roberts, D. C. S., 43  
Robinzon, B., 377  
Rommelspacher, H., 533  
Rose, J. E., 933  
Rozen, R., 117  
Rozenboim, I., 377  
Rusk, I. N., 447
- Saleh, M., 83  
Sampson, A., 933  
Sarfaty, T., 411  
Sato, H., 569  
Schama, K. F., 267  
Schechter, M. D., 361  
Schmidt, W. J., 621  
Schnur, P., 589  
Scotti de Carolis, A., 203  
Seale, T. W., 1017  
See, R. E., 1057  
Segal, D. S., 913  
Sen, P., 867  
Sharpless, N. S., 1067  
Shimizu, H., 1049  
Shippenberg, T. S., 129  
Shirakawa, K., 815  
Shirao, I., 791  
Sierra, V., 727  
Signs, S. A., 361  
Sinton, C. M., 459  
Śmiałowski, A., 95, 585  
Smith, T. L., 827, 913  
Snapir, N., 377  
Snodgrass, S. H., 949  
Söderpalm, B., 259  
Spanos, L. J., 835  
Sperber, E. F., 1067  
Standish, S. M., 717  
Starr, B. S., 849  
Starr, M. S., 849  
Steinberg, J. L., 677  
Stennett, R., 1003  
Stewart, J., 581  
Stewart, R. B., 431  
Strano, R., 1043  
Stripling, J. S., 463
- Tanaka, H., 1049  
Tanaka, M., 569, 791  
Tang, M., 773  
Tapp, W. N., 331  
Tatsuno, T., 1049  
Terry, L. C., 717
- Thompson, T., 643  
Thornton, E. W., 77  
Thornton, J. E., 421  
Ticku, M. K., 233  
Tjølset, A., 601  
Tomkins, D. M., 777  
Toth, E., 323  
Towell, A., 133  
Trampus, M., 861  
Tresguerres, J. A. F., 157  
Triandafillou, J., 301  
Trouiller, G., 699  
Truong, D. D., 993  
Tsuchiyama, K., 491  
Tsuda, A., 569, 791  
Tsumijamaru, S., 569, 791  
Tulen, J. H. M., 9  
Turek, F. W., 901
- Ukai, M., 651  
Upchurch, M., 543
- Vale, A. L., 857  
Vécsei, L., 629  
Velfšek, L., 405  
Vezina, P., 581  
Vignon, J., 699  
Vila, C. J., 365  
Villanúa, M. A., 157  
Virus, R. M., 691  
Visé, F., 415  
Vizi, E. S., 927  
Vogel, W. H., 1071  
van Haaren, F., 707  
van Hest, A., 707  
van Luijtelaar, E. L. J. M., 27  
van Steenis, H. G., 9
- Wadenberg, M.-L., 797  
Wajner, M., 885  
Wallace, D. R., 391  
Wannmacher, C. M. D., 885  
Wawrzyniak, N., 415
- Wee, B. E. F., 901  
Wehner, J. M., 543  
Weiner, I., 55, 65, 123  
Weinstein, D., 1057  
Weinstock, M., 425  
Wellman, P. J., 147, 819  
Wenger, G. R., 241  
Wessinger, W. D., 711  
Whishaw, I. Q., 211  
White, J. M., 479  
White, N. M., 249  
Wickens, A., 77  
Widerlöf, E., 629  
Widjaja, S., 533  
Wilkinson, D. M., 191  
Willner, P., 133  
Winslow, J. T., 919  
Winter, J. C., 87  
Wirtshafter, D., 625  
Wise, R. A., 527, 581, 769  
Wisniewski, H. M., 939  
Witkin, J. M., 309, 971  
Wolffgramm, J., 533  
Wood, R. W., 283  
Woolley, D. E., 367  
Woolverton, W. L., 607, 691  
Wozniak, K. M., 37  
Wurpel, J. N. D., 1067
- Yamada, K., 815  
Yamamoto, B. K., 835  
Yirmiya, R., 17  
Yoburn, B. C., 727  
Yutzenka, G. J., 891
- Zahniser, N. R., 71  
Zimmerberg, B., 293  
Zohar, J., 37  
Zwilling, U., 415